UK tests five-day breast cancer radiotherapy

A groundbreaking five-day breast cancer radiotherapy trial is underway across the United Kingdom, potentially revolutionizing cancer treatment for thousands of patients. The FAST-Forward Boost trial, involving over 1,000 participants across 39 hospitals, aims to shorten the standard three-week radiotherapy course to just five days.

This shorter treatment could drastically reduce the number of hospital visits required, saving patients significant time and money. The trial, led by the Institute of Cancer Research in London and funded by the National Institute for Health and Care Research, will enroll 4,830 participants by 2028. Results are expected in 2033, after a five-year follow-up period.

The UK Department of Health and Social Care announced the trial, highlighting its potential to transform cancer treatment and patient care. Health and Social Care Secretary Yvette Cooper praised the initiative, stating that it demonstrates the UK's commitment to leveraging research to improve cancer treatment. The trial's success could lead to reduced travel costs and time away from work and family for patients, while also freeing up NHS resources to treat more individuals.

Additionally, the government has been focusing on improving breast cancer screening, early diagnosis, and patient support.

While breast cancer screening uptake among women receiving their first invitation has reached a 10-year high of 63.6%, around 40% of women still do not attend their first screening appointment. The UK government is collaborating with the National Institute for Health and Care Research, NHS England, and Breast Cancer Now to explore the use of artificial intelligence in analyzing mammograms and to provide women with the knowledge and support needed to recognize breast cancer symptoms and access information post-treatment.